Molecular engineering of safe and efficacious oral basal insulin
Recently, the first orally-administered ultra-long acting insulin was shown to have clinical efficacy. Here, the authors report the molecular engineering, as well as the biological and pharmacological properties of these insulin analogues.
Main Authors: | Frantisek Hubálek, Hanne H. F. Refsgaard, Sanne Gram-Nielsen, Peter Madsen, Erica Nishimura, Martin Münzel, Christian Lehn Brand, Carsten Enggaard Stidsen, Christian Hove Claussen, Erik Max Wulff, Lone Pridal, Ulla Ribel, Jonas Kildegaard, Trine Porsgaard, Eva Johansson, Dorte Bjerre Steensgaard, Lars Hovgaard, Tine Glendorf, Bo Falck Hansen, Maja Kirkegaard Jensen, Peter Kresten Nielsen, Svend Ludvigsen, Susanne Rugh, Patrick W. Garibay, Mary Courtney Moore, Alan D. Cherrington, Thomas Kjeldsen |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2020-07-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-020-17487-9 |
Similar Items
-
Molecular characterisation of long-acting insulin analogues in comparison with human insulin, IGF-1 and insulin X10.
by: Bo F Hansen, et al.
Published: (2012-01-01) -
Engineering of insulin receptor isoform-selective insulin analogues.
by: Tine Glendorf, et al.
Published: (2011-01-01) -
Systematic evaluation of the metabolic to mitogenic potency ratio for B10-substituted insulin analogues.
by: Tine Glendorf, et al.
Published: (2012-01-01) -
Dually Reactive Long Recombinant Linkers for Bioconjugations as an Alternative to PEG
by: Thomas Kjeldsen, et al.
Published: (2020-07-01) -
Delayed insulin absorption correlates with alterations in subcutaneous depot kinetics in rats with diet‐induced obesity
by: A. K. J. Gradel, et al.
Published: (2019-06-01)